LARTRUVO (olaratumab), monoclonal antibody

Insufficient clinical benefit to justify its reimbursement in the treatment of adults with advanced soft tissue sarcoma, non-eligible for curative treatment by surgery or radiotherapy and not receiving doxorubicin pre-treatment

• LARTRUVO has MA in combination with doxorubicin, in the treatment of adults with advanced soft tissue sarcoma, non-eligible for curative treatment by surgery or radiotherapy and not having received doxorubicin pre-treatment.

• According to the data currently available from a single proof-of-concept study, and pending the results of an ongoing study, addition of LARTRUVO to doxorubicin up to 8 cycles, then continued in monotherapy, does not have a role in the treatment of soft tissue sarcoma, in adults ineligible for curative treatment by surgery or radiotherapy, and not having received doxorubicin pre-treatment.

• There are drug alternatives to this treatment line, in particular doxorubicin alone or in combination.